Improve Research Reproducibility A Bio-protocol resource
- Home
- Protocols
-
Ask a
question
Favorite
An initial HR of 0.868 (12.5% RR reduction at five years) is both clinically important and appropriate for the ATTACK study population. This estimate is based upon current knowledge on the use of aspirin for primary and secondary prevention [26, 31], the risk profile of people with CKD [82] and the results observed in the subgroup of participants in the HOT study who had CKD [52].
Copyright and License information: The Author(s) ©2022
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Do you have any questions about this protocol?
Post your question to gather feedback from the community. We will also invite the authors of this article to respond.
Post a Question0 Q&A
